Zymeworks (ZYME)
(Delayed Data from NSDQ)
$12.54 USD
-0.06 (-0.48%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $12.54 0.00 (0.00%) 4:56 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZYME 12.54 -0.06(-0.48%)
Will ZYME be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Other News for ZYME
Commit To Buy Zymeworks At $7.50, Earn 26.1% Annualized Using Options
Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance
Zymeworks (ZYME) Receives FDA Green Light for New Drug Targeting Liver Cancer
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel ...
Zymeworks announces FDA clearance of IND application for ZW251